This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

I think it's good news as well...a couple of big hitters appointed to the panel (advice plus all the contacts that go with it). Looking forward to next 2 weeks or so.

I was having a bad day but this has cheered me up a bit.
The wifes got me to hire a carpet cleaner ! If these come good she can have new carpets,would save me a job !

Buy her a new carpet DB, far easier for yourself.

Good news here today. Cant be far off the biggy now. Ive sent EK a develish warning note. Lets see if he closes today or monday.

cheers GF.

GF

If he dosen't he can add MMG to his list of failures that's for sure. Are you keeping an eye on GMC.

LOL

MS

Hi Mickey yup thats for sure. Your a member of tips arent you?, will you let us please know if he closes today or monday.

Not in GMC mickey not in any gaming stocks now, I know Evil likes this one though, long I meant.

cheers GF.

Yes I am and will let you know if anything happens.

LOL
MS

I`m not sure he will close just yet,as for GMC Mickey i think i timed that just right got back in Tuesday at 10.55 .

From the other side. A couple of very good posts, read on.....

el magnifico - 3 Mar'06 - 10:23 - 6976 of 6984


What a difference a year makes ! Twelve months ago, MMG was pumping out press releases and the stock became a momentum play after Walter's big tip and then got picked off by professional shorts.

A year on, the MMG story is no longer sexed up by PR - as the lack of sizzle from today's announcement shows. This is the first product-related RNS since November's SAFC ruthenium manufacturing announcement.

Today's MMG is more professional (apart from website - see previous posts)and far less promotional. The key takeaway from this announcement and the MMG is making all the right steps. A quick recap :

On the foundation of a firm funding base, following September 2005's 10 million placing at 1.35p, MMG has continued constructing strong patent positions for its major therapeutic areas in Genvax and Oncosense, has extended the Genvax trial (with an endpoint this month, so today's press release will probably not be the last one in March)and is set to announce the start of Phase II trials for Oncosense's ruthenium compounds.

A younger junior management team was put in place in 2005 at MMG. Today's announcement validates the Genvax therapy at an academic level (more on this on 16/17th March) and demonstrates organisational skills by introducing an international dimension. Strong IP, rigorous and carefully-constructed trials, high-quality partners (Sigma-Aldrich producing ruthenium compounds) - these are the building blocks for a company which believes in its own future. Take a bow, DB.

Looking at the recent volumes and trading pattern, MMG seems to be under quiet, careful daily accumulation (look at recent after-hours block reports). That is the only way institutional buyers can build a meaningful position in a small capitalisation stock.

How far have we come in the last year ? Let's tick the boxes : Finance, IP, Partners, Management, Trial extension, academic endorsement, good recent accumulation characteristics. Price action ? Well, the share price is the same today as it was on 15th March 2005 !

And how about Prospects ? "Discussions with major pharmaceutical marketing partners are ongoing". No change there, but one year closer to pay-dirt.

The risk/reward has shifted dramatically in favour of owning a long-term position in MMG since September 2005. The move from 1.35 to 1.84 is trivial in the context of the upside potential.

Do yourself a favour.....

el


A0469514 - 3 Mar'06 - 11:23 - 6979 of 6984


Yes agreed, good posts el magnifico and bolador.

I usually skip the 'notes to editors' and had not read them this time. We have had a few hints through various sources previously but that really is a stunningly optimistic sumary of the Genvax results. I think it is worth repeating in full

A clinical trial for patients with lymphoma has shown that a DNA vaccine using
this technology produced no toxic effects, only minor side effects with no
patient being withdrawn from the trial, and with the majority of patients
remaining in remission. A preliminary examination of blood samples from the
lymphoma patients has shown that the new vaccine stimulated both an antibody
response and a cytotoxic T-lymphocyte response, the latter "heavy weapons" of
the immune system are seen to be essential in the treatment of cancer.

If it is true, it has got to be a blockbuster therapy, surely, which every cancer patient will want to get access to. And really, it has to be true because there is no way , these days, that a company can put out a statement like that without the test results to back it up.

No wonder Cancer Research UK (who control the news flow) seems to be trying to keep things quiet for now. Their telephone lines are going to get jammed when this hits the media properly. For now though, there is still time to aquire a stake in this company at a bargain price.

Xylos

EK did not mention MMG in his diary today he is therefore still short.
Have a good one guys it's getting neat G & T time for me and a ruby murry for supper. Can't be all bad.

MS

What with chicken and lashings of Vindaloo, superb.

cheers GF.

049balt, your e-mail messager isnt activated. I cant reply unless you activate it.

cheers GF.

goldfinger, got that sorted, thanks.

Cheers 049.

GF.

This is a good post worth a read.

el magnifico - 6 Mar'06 - 12:44 - 7003 of 7006


Another example of Big Pharma (Novartis being one of the companies where newly-appointed GenVax Scientific Advisory panel member Prof Christoph Huber also hangs his hat!) paying big money for anti-cancer biotech potential.

I would note that the key differences between the therapy cited in the text and MMG's GenVax is that GenVax's proprietary technology is wrapped up in patents, the therapy actually works today (at the bespoke vaccine level today, but I expect will do so as a broad vaccine, too) and MMG owns a controlling 58 % of GenVax.

Just on the strength of the above, MMG would seem to be wildly undervalued, without taking Oncosense, Viratis and any twinkles in DB's eye into account. Read on...


"Infinity Pharmaceuticals Inc. will receive as much as $400 million under a pact with Novartis AG to develop drugs to attack a protein that's key to the survival of many types of cancer cells.

The two biotechnology concerns are expected to announce the agreement today.

During the first two years of the collaboration, closely held Infinity, of Cambridge, Mass., will receive $30 million from the Swiss drug giant in upfront licensing fees, research funding and an equity investment. Major pharmaceutical makers, some of them stifled in traditional routes of developing new drugs, are increasingly turning to smaller biotech companies to help fill their pipelines.

Total payments from Novartis could reach $400 million if Infinity meets certain goals related to actual drug development and commercialization. Novartis has also agreed to invest an undisclosed amount in a public offering of Infinity shares, expected in the next two years.

The funding from Novartis boosts Infinity's plans to join a long-running industry effort to find or develop a compound that will inhibit the protein Bcl-2, whose overproduction in cancer cells helps them survive and resist treatment.

Many pharmaceutical concerns and research institutions have related drugs in various stages of development, but the complex interaction of the proteins has long challenged researchers. Loren Walensky, a physician and scientist at Dana Farber Cancer Institute in Boston, said science is getting closer to cracking the problem but noted that 20 years after the protein was identified as a contributing cause to cancer, there still isn't an approved drug "that inhibits Bcl-2 and renders cancer cells more vulnerable."

Jeremy Levin, global head of strategic alliances for the Novartis Institutes for BioMedical Research, said Infinity "has assembled an excellent team of not only people who make chemistry, but people who understand drug discovery."

The agreement is the second between the two companies. Last year, Novartis, with annual sales of $32 billion, agreed to pay Infinity more than $10 million to help it design chemical compounds for use in broader drug development. Novartis will have an ownership stake of less than 10% in the company as a result of the two pacts, Infinity executives said.

Infinity, founded in 2001 and specializing in cancer, has also forged collaborations in recent years with Amgen Inc., Thousand Oaks, Calif., and Johnson & Johnson, New Brunswick, N.J.

Novartis last year entered into 195 collaborations with academic centers and small biotech companies in 20 countries."

The clock is ticking.....

el

Good post Mickey.

cheers GF.

Yet more info from the other side.

A0469514 - 6 Mar'06 - 22:12 - 7008 of 7009


everton, here are a few lightly edited snippets from MW's article. His site is at www.michaelwalters.com.

The association of Prof Huber and Prof Levy with Genvax has highly encouraging implications for Professor Stevenson and her team, and for MMI. Such people do not become associated with anything but the best. We dont know what will emerge at the conference on March 16/17, but these appointments suggest it is unlikely to be discouraging.

Meanwhile, there is an interesting smattering of new information in the list of Genvax DNA vaccines which are now in trials. In November we learnt from Best that there were trials for five cancers. Now there are at least nine. The list includes lung, colon, pancreas, oesophageal, head and neck, breast, prostate, lymphoma and myeloma. That covers 75% of the main causes of death from cancer.

The programme, then, has broadened. That would not be happening if we were looking at unsuccessful trials.

This is confirmed by comments from the company that the lymphoma trial produced no toxic effects (note NO toxic effects) only mild side effects with no patient being withdrawn from the trial, and the majority of patients (not all) remaining in remission. A preliminary examination of blood samples showed, crucially, both an antibody response and cytotoxic T-lymphocyte response.

The breadth of trials suggests that this is indeed a platform technology which could be widely used, and might perhaps be of value to many companies.

Mr Walters still sounds pretty excited to me. I certainly am!

Xylos

I`m sure todays news is another small but good step towards building a solid foundation.
This slow rise in SP and recent news will all help keep the shorters away.

Medical Marketing Int'l Group PLC
09 March 2006




For Immediate Release 9 March 2006


MMI to sell interests in Bioscience VCT


Medical Marketing International Group plc ("MMI") (AIM: MMG), the Cambridge,
UK-based pharmaceutical development company focussed on cancer and infection,
today announces that it has reached conditional agreement with Bioscience VCT
plc ("the VCT") and Octopus Asset Management Limited ("Octopus") whereby MMI
will sell its interests in the VCT to enable it to focus on its core business of
developing its portfolio of therapeutics.


MMI has provided technical due diligence services to the VCT in return for fees
and a carried interest in the VCT. When the new agreement becomes unconditional
MMI will cease to provide services to the VCT and will forego its carried
interest in the VCT. In return, the VCT and Octopus have agreed to:


Pay MMI an undisclosed sum
Indemnify, keep indemnified and hold MMI harmless from and against
liabilities arising out of and/or in connection with the services, except
for any investment decisions made by the VCT after relying solely on due
diligence performed by MMI
Table a resolution at the Annual General Meeting of the VCT for the
purpose of considering changing the company name to exclude the word
"Bioscience" (which is associated with MMI) with a recommendation from
directors of the VCT for shareholders to vote in favour of the resolution



David Best Chairman of MMI commenting on this announcement said: "As noted in
our recent Interim results and due to the change in investment policy already
implemented by the VCT, the work performed for the VCT has become increasingly
less relevant to MMI's core business.


The main focus and value-driver remains through our maturing therapeutic
pipeline, which includes Genvax for DNA cancer vaccines, now in clinical trials
covering 75% of major cancers, with further pre-clinical work for
life-threatening viral and bacterial infections; and with our lead ruthenium
compounds due to enter clinical trials this year.


Our hands-on approach with MMI's drug development portfolio has clearly worked
as we now have one of the largest cancer pipelines in the business. Today's
Agreement will enable us to focus entirely on our in-house programmes and by
demonstrating continued progress in the clinic and with commercial partners, the
potential upside for shareholders will be greater."


For further information, please contact:

David Best - Executive Chairman
MMI Group Tel: +44 (0)1223 477677
www.mmigroup.co.uk

Lisa Baderoon / Rebecca Skye Dietrich
Buchanan Communications Tel: +44 (0)20 7466 5000
lisab@buchanan.uk.com

A good move I feel.

cheeers GF.

" We now have one of the largest cancer pipelines in the business"

Give me a reason why this share is not trading at 1000-1500p a share..?

That will do me Mitzy. If it gets that high I'll have the rust spots done on my car. I might even treat the missus to a new hoover.

MS